<DOC>
	<DOCNO>NCT01733589</DOCNO>
	<brief_summary>Resistance hypoxic tumor cell radiation significant reason failure local control tumor , especially squamous cell carcinoma . Preclinical model show Endostar may transiently `` normalize '' tumor vasculature make efficient oxygen delivery , thereby provide window opportunity enhance sensitivity radiation treatment . This study evaluate safety , toxicity , efficacy addition Endostar Continued Pumping Vein standard CCRT regimen patient unresectable stage III NSCLC .</brief_summary>
	<brief_title>Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT Unresectable Stage III NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>untreated histologic cytologic NSCLC verify inoperable stage IIIA IIIB NSCLC measurable disease RECIST 18~70 year age ECOG PS 0 1 absolute neutrophil count ( ANC ) ≥1500/μL , hemoglobin ≥10gm/dL , platelet ≥100,000/μL serum creatinine ≤1.25 time upper limit normal ( ULN ) , calculate creatinine clearance ( CrCl ) ≥60ml/min bilirubin 1.5×ULN , AST ALT less 2.5×ULN , alkaline phosphatase le 5×ULN forced vital capacity 1 second ( FEV1 ) high 0.8 L CB6 normal Written inform consent history malignant disease contraindication chemoradiotherapy distant metastasis malignant pleural and/or pericardial effusion pregnant nursing preexist bleeding diatheses coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Recombinant human endostatin</keyword>
	<keyword>Non-small-Cell Lung Cancer</keyword>
	<keyword>chemoradiotherapy</keyword>
</DOC>